Key Insights

Highlights

Success Rate

80% trial completion

Published Results

137 trials with published results (26%)

Research Maturity

266 completed trials (51% of total)

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 49/100

Termination Rate

12.5%

65 terminated out of 518 trials

Success Rate

80.4%

-6.1% vs benchmark

Late-Stage Pipeline

24%

126 trials in Phase 3/4

Results Transparency

52%

137 of 266 completed with results

Key Signals

137 with results80% success65 terminated

Data Visualizations

Phase Distribution

378Total
Not Applicable (84)
Early P 1 (5)
P 1 (66)
P 2 (97)
P 3 (74)
P 4 (52)

Trial Status

Completed266
Unknown67
Terminated65
Recruiting49
Withdrawn31
Active Not Recruiting22

Trial Success Rate

80.4%

Benchmark: 86.5%

Based on 266 completed trials

Clinical Trials (518)

Showing 20 of 20 trials
NCT06409026Phase 4CompletedPrimary

Sotatercept on Central Cardiopulmonary Performance and Peripheral Oxygen Transport During Exercise in Pulmonary Arterial Hypertension

NCT01712620Phase 2RecruitingPrimary

Spironolactone for Pulmonary Arterial Hypertension

NCT07464184Not ApplicableNot Yet Recruiting

Evolution of Hypoxic Burden and Sympathetic/Parasympathetic Balance in Patients With Pulmonary Hypertension

NCT06137742Phase 1Active Not RecruitingPrimary

A Study to Learn About the Study Medicine Called PF-07868489 in Healthy Adult People and in People With Pulmonary Arterial Hypertension

NCT03626688Phase 3Completed

A Study Evaluating the Efficacy and Safety of Ralinepag to Improve Treatment Outcomes in PAH Patients

NCT05649748Phase 2Active Not RecruitingPrimary

An Extension Study of Treprostinil Palmitil Inhalation Powder (TPIP) for Pulmonary Arterial Hypertension (PAH)

NCT06907693CompletedPrimary

The Effects of Drug Candidate CS1 on Lung Structure and Function Utilizing FRI

NCT04273945Phase 3Active Not RecruitingPrimary

Outcome Study Assessing a 75 Milligrams (mg) Dose of Macitentan in Patients With Pulmonary Arterial Hypertension

NCT03492177Phase 2Active Not RecruitingPrimary

A Clinical Study of to Confirm the Doses of Selexipag in Children With Pulmonary Arterial Hypertension

NCT04816604Phase 2Active Not RecruitingPrimary

Open-label Extension Study of GB002 in Adult Subjects With Pulmonary Arterial Hypertension (PAH)

NCT05934526Phase 3CompletedPrimary

Efficacy and Safety of Seralutinib in Adult Subjects With PAH (PROSERA)

NCT06683040Phase 2Active Not RecruitingPrimary

Evaluation of the Efficacy and Safety of Oxacom® in Patients With Pulmonary Arterial Hypertension

NCT03045029Active Not RecruitingPrimary

ADAPT - A Patient Registry of the Real-world Use of Orenitram®

NCT04691154Phase 3Active Not RecruitingPrimary

A Phase 3 Study to Evaluate the Safety and Tolerability of L606 in Subjects With PAH or PH-ILD

NCT03838445Not ApplicableRecruitingPrimary

Reducing Right Ventricular Failure in Pulmonary Arterial Hypertension (RELIEVE-PAH)

NCT05147805Phase 2CompletedPrimary

A Study to Evaluate the Efficacy, Safety and Pharmacokinetics of Treprostinil Palmitil Inhalation Powder in Participants With Pulmonary Arterial Hypertension

NCT01208792Not ApplicableCompletedPrimary

Auto-immunity and Pulmonary Arterial Hypertension

NCT06549452Not ApplicableRecruitingPrimary

Mobile Health Intervention to Improve Exercise in Pediatric PH

NCT07218029Phase 3RecruitingPrimary

A Clinical Study of Sotatercept (MK-7962) in People With Pulmonary Arterial Hypertension (MK-7962-038)

NCT05587712Phase 2RecruitingPrimary

Study to Evaluate Sotatercept (MK-7962) in Children With Pulmonary Arterial Hypertension (PAH) (MK-7962-008)

Scroll to load more

Research Network

Activity Timeline